The Latest Breaking News from MRK

This article covers three stocks included in the S&P 500 which are showing exceptionally low P/E ratios of 20 or less, indicating potential buys.

Despite Merck’s recent underperformance relative to the S&P 500 Index, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Merck has considerably underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more.

Merck & Co. is scheduled to announce its fourth-quarter results next month, with analysts anticipating significant earnings growth.

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability and long-term growth potential. Thus, one could consider adding these three fundamentally sound blue-chip stocks, AbbVie (ABBV), Merck & Co. (MRK), and Johnson & Johnson (JNJ), with Strong Buy ratings from…